Arandomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation

Cancer Management and Research

Volumn 6, Issue 1, 2014, Pages 181-190

  Mason, Jay W ^a   Moon, Thomas E ^b   O'Boyle, Erin ^c   Dietz, Albert ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Tarizona EHealth Services   (United States)

^c AP Pharma   (United States)

^d Spaulding Clinical Research ^*  (United States)

Author keywords

APF530; Chemotherapy induced nausea and vomiting; Extended release; Granisetron; QTc interval; Subcutaneous

Indexed keywords

GRANISETRON; MOXIFLOXACIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ERYSIPELAS; FEMALE; HEMATOMA; HUMAN; HUMAN EXPERIMENT; INJECTION SITE CONTUSION; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 84897436783     PISSN: None     EISSN: 11791322     Source Type: Book Series    
DOI: 10.2147/CMAR.S58071     Document Type: Article

References (29)

1. Roscoe JA, Morrow GR, Colagiuri B, et al. Insight in the prediction of chemotherapy-induced nausea. Support Care Cancer. 2010;18(7): 869-876.
2. Hesketh PJ, Gandara DR. Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst. 1991;83(9):613-620.
3. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. v 1.2014. Fort Washington, PA: NCCN; 2013. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
4. Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21 Suppl 5:v232-v243.
5. Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198.
6. Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther. 2000;295(2): 614-620.
7. Kytril (granisetron hydrochloride) tablets oral solution [prescribing information]. Nutley, NJ: Roche Pharmaceuticals; 2010.
8. Kytril (granisetron hydrochloride) injection [prescribing information]. San Francisco, CA: Genentech, Inc.; 2011.
9. Zofran (ondansetron hydrochloride) injection [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
10. Zofran (ondansetron hydrochloride) tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
11. Anzemet injection (dolasetron mesylate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2011.
12. Anzemet tablets (dolasetron mesylate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; 2011.
13. US Food and Drug Administration (FDA). FDA drug safety communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) [web page on the Internet]. Silver Spring, MD: FDA; 2010 [updated December 22, 2010]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm. Accessed February 28, 2014.
14. FDA. Safety: Kytril (granisetron hydrochloride) injection, tablets and oral solution [web page on the Internet]. Silver Spring, MD: FDA; 2009 [updated October 21, 2009]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm187526.htm. Accessed February 28, 2014.
15. FDA. FDA drug safety communication: abnormal heart rhythms may be associated with use of Zofran (ondansetron) [web page on the Internet]. Silver Spring, MD: FDA; 2011 [updated June 29, 2012]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm. Accessed February 28, 2014.
16. FDA. FDA drug safety communication: updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products [web page on the Internet]. Silver Spring, MD: FDA; 2012 [updated December 6, 2012]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm330049.htm. Accessed February 28, 2014.
17. Aloxi (palonosetron HCl) injection [prescribing information]. Woodcliff Lake, NJ: Eisai Pharmaceuticals; 2008.
18. Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study. Eur J Cancer. 2003;39(7):927-931.
19. Carmichael J, Philip PA, Forfar C, Harris AL. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol. 1995;37(1-2): 134-138.
20. Carmichael J, Harris AL. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol. 2004;53(2):123-128.
21. Jantunen IT, Kataja VV, Muhonen TT, Parviainen T. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol. 1996;37(5):502-504.
22. Upward JW, Arnold BD, Link C, Pierce DM, Allen A, Tasker TC. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer. 1990;26 Suppl 1:S12-S15.
23. Friedman CJ, Burris HA 3rd, Yocom K, Blackburn LM, Gruben D. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy. Oncologist. 2000;5(2):136-143.
24. Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res. 2012;18(10):2913-2921.
25. Grous J, Riegel E, Gabrail N, et al. Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV). J Clin Oncol. 2009;27(Suppl):abstr 9627.
26. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Rockville, MD: US Department of Health and Human Services, FDA, CDER, CBER; 2005. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf. Accessed February 28, 2014.
27. International Conference on Harmonization. Guidance for Industry: E6 Good Clinical Practice: Consolidated Guidance; 2006. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM073122.pdf. Accessed March 17, 2014.
28. World Medical Association (WMA). WMA Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire: WMA; 2008. Available from: http://www.wma.net/en/30publications/10policies/b3/. Accessed February 28, 2014.
29. Gabrail N, Yanagihara RH, Cooper W, et al. Pharmacokinetics (PK), tolerability, and efficacy of APF530 in patients receiving moderately (MEC) and highly (HEC) emetogenic chemotherapy: Phase II trial results. J Clin Oncol. 2013;31(Suppl):abstr e20518.